DreaMed Diabetes

What DreaMed Diabetes does

DreaMed Diabetes Ltd. is an Israel-based, venture-backed software company founded in 2014 that builds an AI-driven clinical decision-support platform for diabetes management. The platform ingests continuous glucose monitoring (CGM) data — most notably from Abbott's FreeStyle Libre devices via a data integration partnership signed in August 2024 — alongside other patient data, and outputs expert-level insulin treatment recommendations intended for use by healthcare providers and patients. Its founding leadership combines deep clinical diabetes research credentials (CSO Moshe Phillip, Chief Medical R&D Officer Revital Nimri) with product and engineering talent, and the company has been funded by strategic and impact-oriented investors including Medtronic ($2M, 2015), Millhouse ($3.3M, 2016), The Helmsley Charitable Trust ($5M, 2020), and most recently eHealth Ventures ($3M lead, 2024).

DreaMed generates revenue through what appears to be a B2B enterprise software model — subscription or licensing of its AI platform to healthcare systems and device partners — though pricing is not publicly disclosed. Its go-to-market combines enterprise field sales into U.S. healthcare providers (e.g., Yale New Haven Health) with API-first integration partnerships that embed its dosing algorithms into medical-device ecosystems. The company operates at small scale (11-50 employees, headquartered in the Tel Aviv / Petah Tiqva area) and is at an early commercial stage, having only recently converted its first two publicly named commercial relationships. The corporate website now redirects to dreamed.ai, suggesting a possible broader rebrand or platform expansion beyond diabetes.

Strategically, DreaMed is positioning itself as the AI dosing and decision-support layer for the global automated insulin delivery market — a market valued at approximately $989M in 2025 and projected to grow at a 10.5% CAGR to roughly $2.7B by 2035. Its near-term priorities, as stated in the August 2024 funding announcement, are U.S. expansion, platform improvement, and deepening partnerships with device makers and health systems. The combination of clinical-research depth, anchor partnerships with category leaders, and a focused TAM positioning is the company's primary investment thesis, tempered by small scale, undisclosed revenue, and limited public validation of its AI models.

Name

DreaMed Diabetes

Legal name

DreaMed Diabetes Ltd.

Website

https://dreamed-diabetes.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

DreaMed Diabetes is an Israel-based AI software company founded in 2014 that builds a clinical decision-support platform converting continuous glucose monitoring data into expert-level insulin treatment recommendations for healthcare providers and diabetes patients, integrated with Abbott FreeStyle Libre CGM devices and deployed into U.S. health systems.

Ownership category

akta.pro rank

Product category

AI Diabetes Management Software

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

akta.pro secondary industries

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Type 1 Diabetes Care (HLAKADAB)

Keywords

• AI diabetes management
• Insulin therapy optimization
• Clinical decision support
• CGM data analytics
• Diabetes care platform

Headquarters

HQ city

Petah Tiqva

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. AI-Driven Diabetes Care Platform: Software platform providing AI-driven diabetes care solutions for healthcare providers and patients, with revenue likely generated through subscription licensing or per-patient usage fees

Go-to-market motion2 records

Distribution channels1 record

Core offering

DreaMed Diabetes builds an AI-driven software platform that transforms continuous glucose monitoring (CGM) and other patient data into expert-level insulin treatment recommendations. The platform integrates with CGM devices such as Abbott's FreeStyle Libre to provide clinical decision support and automated insulin therapy optimization for healthcare providers and diabetes patients.

Product overview

DreaMed Diabetes offers a unified AI-driven software platform for diabetes care management. The core product is an AI platform that transforms continuous glucose monitoring and patient data into expert-level insulin treatment recommendations, enabling automated diabetes management and clinical decision support for healthcare providers.

Differentiator

Problem solved

Functional benefit

Products and services

• DreaMed AI-Driven Diabetes Care Platform An AI-driven platform for diabetes treatment that transforms patient data into expert-level insulin treatment recommendations. The platform integrates with continuous glucose monitoring devices and provides clinical decision support for diabetes management, aimed at healthcare providers and patients.

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• AbbottcoreTechnology or Integration · 1 August 2024Data integration partnership enabling data sharing from Abbott's FreeStyle Libre CGM devices to DreaMed's AI platform. This integration allows continuous glucose monitoring data to flow directly into DreaMed's diabetes treatment system for AI-driven insulin optimization.
• Yale New Haven HealthcoreStrategic or Co-development Partner · 1 August 2024Healthcare system partnership for building collaborative relationships in diabetes care. DreaMed is developing partnerships with Yale New Haven Health to integrate AI-driven diabetes care solutions into clinical workflows.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• Abbott Diabetes Care: Abbott's FreeStyle Libre is the CGM franchise that DreaMed integrates with. While not a direct competitor in dose advice, Abbott's strategic direction on whether to build or buy AI dosing is a critical determinant of DreaMed's trajectory.

Broad incumbents

• Roche Diabetes Care: Roche's Accu-Chek smart insulin pen and mySugr app bundle connected diabetes management. A broad incumbent offering connected insulin delivery and decision support that overlaps with DreaMed's clinical workflow positioning.
• Insulet: Insulet's Omnipod 5 integrates an automated insulin delivery algorithm directly into its tubeless pump. A relevant incumbent showing how dosing AI is increasingly bundled with hardware.
• Tandem Diabetes Care: Tandem's Control-IQ technology is an AI-based automated insulin dosing algorithm integrated into its t:slim pump. Represents the bundled, hardware-attached approach that competes with DreaMed's standalone AI dose advisor.
• Medtronic: Medtronic's MiniMed 780G is an AI-driven closed-loop AID system with embedded dosing algorithms. As a former DreaMed investor and a major incumbent in diabetes technology, it represents both a partner/competitor dynamic relevant to DreaMed's positioning.

Direct peers

• Bigfoot Biomedical: Bigfoot Unity offers AI-driven insulin dose decision support via a smart pen cap system. Directly comparable to DreaMed as a connected, AI-first diabetes therapy optimization platform targeting similar patients and providers.
• Diabeloop: Diabeloop develops an AI-based automated insulin delivery and decision-support algorithm embedded in pump systems. Highly comparable to DreaMed's AI insulin recommendation engine, with the same patient population and clinical use case.
• CamDiab (CamAPS FX): CamDiab's CamAPS algorithm is an AI-driven closed-loop dosing app for people with Type 1 diabetes. Direct peer in AI-based personalized insulin therapy decision support.
• Hygieia (d-Nav): Hygieia's d-Nav is an AI insulin dose adjustment service for Type 2 diabetes patients, similar in function to DreaMed's AI insulin treatment recommendations and serving an overlapping provider base.

Emerging players

• Beta Bionics: Beta Bionics' iLet bionic pancreas uses algorithmic insulin dosing with minimal user input. Comparable emerging competitor in the AI-driven insulin decision support space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/DreaMedDiabetes
• Facebookfacebook.com/686958088038870
• LinkedInlinkedin.com/company/5220173

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DreaMed Diabetes